Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 6/20 | 0.43 |
| ▸ | MMP13 | P45452 | 6/20 | 0.43 |
| ▸ | MMP1 | P03956 | 5/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.43 |
| ▸ | HTR1A | P08908 | 11/20 | 0.41 |
| ▸ | HTR2A | P28223 | 11/20 | 0.41 |
| ▸ | HTR7 | P34969 | 11/20 | 0.41 |
| ▸ | HTR6 | P50406 | 11/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25318594 | 0.89 | IP6K1 (0.41) | MMP9MMP13MMP1ADAM17HTR1A | |
| SCHEMBL30506975 | 0.89 | IP6K1 (0.41) | MMP9MMP13MMP1ADAM17HTR1A | |
| SCHEMBL26036192 | 0.85 | HTR1A (0.45) | MMP9MMP13MMP1ADAM17HTR1A | |
| SCHEMBL30506905 | 0.77 | MMP13 (0.49) | MMP9MMP13MMP1ADAM17 | |
| SCHEMBL25319640 | 0.77 | MMP13 (0.49) | MMP9MMP13MMP1ADAM17 | |
| SCHEMBL26036190 | 0.76 | HTR7 (0.36) | HTR7 | |
| SCHEMBL25317717 | 0.75 | HTR1A (0.48) | MMP9MMP13MMP1ADAM17HTR1A | |
| SCHEMBL25317994 | 0.75 | RAB9A (0.40) | MMP9MMP13MMP1ADAM17BACE1 | |
| SCHEMBL30507123 | 0.75 | RAB9A (0.40) | MMP9MMP13MMP1ADAM17BACE1 | |
| SCHEMBL25934672 | 0.75 | RAB9A (0.40) | MMP9MMP13MMP1ADAM17BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | MMP9 2139/4885MMP13 835/4885MMP1 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.